Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 4, Number 4—December 1998

Synopsis

Rotavirus

Umesh D. ParasharComments to Author , Joseph S. Bresee, Jon R. Gentsch, and Roger I. Glass
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 7

Percentage of children with adverse reactions during 5 days of surveillance following each of three doses of tetravalent rhesus-rotavirus vaccine (RRV-TV) or placebo. A) percentage with fever (as measured by axillary temperatures).*On day 4, 2.2% of RRV-TV recipients vs. 0.2% of placebo recipients became febrile (p = 0.02). B) percentage with diarrhea. C) percentage with vomiting. Adapted from (43).

Figure 7. Percentage of children with adverse reactions during 5 days of surveillance following each of three doses of tetravalent rhesus-rotavirus vaccine (RRV-TV) or placebo. A) percentage with fever (as measured by axillary temperatures).*On day 4, 2.2% of RRV-TV recipients vs. 0.2% of placebo recipients became febrile (p = 0.02). B) percentage with diarrhea. C) percentage with vomiting. Adapted from (43).

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO